Friday, January 28, 2022 7:43:55 AM
Senti, what I am telling you is the idea that this misallocation was spread out over 10 years is not possible. Do I need to describe simple block randomization? Picture the first 20 patients being skewed 15 vs 5, guess what happens during the next two blocks of 20.
The more complex acceptable randomization techniques only go further in making sure balance by all available parameters is maintained. A 32 patient skew by randomization is impossible.
Either FDA did not allow the final 17 patients randomized to placebo in the trial (highly, highly doubtful) or they removed placebo. These are your options to get to where we landed. The company, patients and physicians would be completely unaware of what took place, officially, thus integrity of the blind maintained. How regulators choose to view the population is up to them, but the Intent to Treat was DCVax alone for the final cohort.
Anyone believing that an error n the randomization schema occurred is not living in the 21st century of clinical research, no offense intended.
The more complex acceptable randomization techniques only go further in making sure balance by all available parameters is maintained. A 32 patient skew by randomization is impossible.
Either FDA did not allow the final 17 patients randomized to placebo in the trial (highly, highly doubtful) or they removed placebo. These are your options to get to where we landed. The company, patients and physicians would be completely unaware of what took place, officially, thus integrity of the blind maintained. How regulators choose to view the population is up to them, but the Intent to Treat was DCVax alone for the final cohort.
Anyone believing that an error n the randomization schema occurred is not living in the 21st century of clinical research, no offense intended.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
